查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988144

心臟輔助設備市場：2026-2032年全球市場預測（按產品類型、操作模式、治療持續時間、臨床應用和最終用戶分類）

Cardiac Assist Devices Market by Product Type, Mode Of Operation, Therapy Duration, Clinical Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，心臟輔助設備市場價值將達到 16.5 億美元，到 2026 年將成長到 17.5 億美元，到 2032 年將達到 26.3 億美元，複合年成長率為 6.84%。

主要市場統計數據
基準年 2025 16.5億美元
預計年份：2026年 17.5億美元
預測年份 2032 26.3億美元
複合年成長率 (%) 6.84%

全面部署心臟輔助設備，重點關注臨床進步、技術融合以及相關人員的策略重點。

心臟輔助裝置已從一種小眾的救命療法發展成為現代晚期心臟衰竭治療的核心要素。過去20年間，裝置小型化、手術技術和術後護理的進步改變了臨床預期，並擴大了可從機械循環支持中獲益的患者群體。同時，影像學、血流動力學監測和抗凝血治療管理的進步進一步提高了手術安全性，使得更早、更果斷的臨床介入成為可能。

對正在重塑心臟輔助設備創新和醫療保健服務的技術、臨床和報銷制度變革的融合進行了詳細分析。

由於技術、臨床實踐和衛生經濟學等多面向因素的融合，心臟輔助裝置領域正經歷著變革性的轉變。幫浦組件的小型化和經皮入路技術的改進，拓展了微創輔助性治療的適應症，使急性補償患者能夠早期療育，並提供可在傳統手術室外進行的過渡治療策略。同時，臨床醫師正基於風險分層工具和生物標記的進步，重新思考患者選擇標準，從而實現更個人化的裝置選擇和治療時機。

2025年美國關稅調整的累積分析及其對心臟輔助設備供應鏈和籌資策略的策略影響

美國宣布的2025年一系列關稅調整將對整個心臟輔助設備生態系統的供應鏈設計、採購決策和籌資策略產生實際影響。依賴國際供應鏈採購精密組件、泵浦組件或專用耗材的製造商，如果無法自行承擔或將關稅增加的成本轉嫁給買家，其利潤率可能會面臨壓力。因此，醫療系統和集團採購組織的採購團隊將更嚴格地審查總交付成本，而供應商也將重新審視合約條款和對沖策略以管理風險。

關鍵細分洞察，闡明產品類型、運作模式、臨床應用、治療持續時間以及實施過程中對最終用戶的影響。

嚴謹的細分框架闡明了產品系列、運作模式、臨床目標、治療時間長度和最終用戶如何相互作用，從而影響部署路徑和研發優先順序。根據產品類型，設備類別涵蓋雙心室輔助裝置、左心室輔助裝置、經皮心室輔助裝置、右心室輔助裝置和人工心臟，經皮輔助裝置又可根據 Impella 和 TandemHeart 等平台進一步細分。每個產品類型都有其獨特的應用情境、手術流程和服務預期，這些因素都會影響醫療機構確定部署優先順序。

一份全面的區域性洞察報告，概述了監管、報銷和臨床生態系統方面的差異如何影響全球心臟輔助設備的採用。

區域趨勢對監管方式、報銷框架、臨床醫生診療模式和供應鏈設計產生顯著影響，從而為醫療器材的商業化和推廣應用開闢了獨特的路徑。在美洲，先進的心臟中心持續推動微創和永續支援策略的早期應用，這得益於完善的臨床註冊登記系統、不斷完善的保險政策以及豐富的專業外科技術。這種環境正在推動相關技術的發展，這些技術在改善臨床療效和降低再入院率方面展現出顯著優勢。

企業級策略洞察，揭示設備開發公司在產品創新、合作夥伴關係和不斷演變的服務模式方面的趨勢。

關鍵產業相關人員正在採取互補策略，包括產品創新、服務拓展以及與臨床中心建立合作關係，以加速實證醫學證據的產生和應用。領先的醫療設備製造商正投資於幫浦設計、生物相容性材料和整合感測技術的迭代改進，以減少併發症並簡化植入過程。同時，外科醫療設備專家和經導管治療創新者正在探索混合技術和簡化的入路平台，以降低手術複雜性並擴大可進行此類手術的醫生範圍。

為產業領導者提供可操作的建議，以提高產品相關性、供應鏈韌性、證據產生和服務型經營模式。

產業領導者應優先考慮一系列切實可行的舉措，以在採購環境有限的情況下，維持臨床有效性、保護利潤率並加快產品部署。首先，他們應投資於模組化產品策略，實現關鍵子系統（例如控制器和感測器）的分階段升級，從而減少整套系統更換的需求，同時提升醫院的生命週期價值。其次，他們應制定全面的證據計劃，該計劃不僅涵蓋關鍵臨床試驗，還包括註冊研究、真實世界臨床結果以及直接解決支付方和醫院採購疑慮的衛生經濟學分析。

一種透明且多方面的調查方法，結合了與臨床醫生的直接訪談、註冊分析、監管審查和基於情境的評估。

本調查方法整合了多種證據來源，以確保為臨床、商業和監管相關人員提供可操作、可靠且可重複的見解。主要研究包括對心臟外科醫生、心臟衰竭專家、介入性心臟病專家和採購經理進行結構化訪談，以收集關於器械性能、手術流程和推廣障礙的實際觀點。這些定性資訊將與臨床文獻綜述、同行評審的試驗結果和器械註冊資訊進行交叉比對，以檢驗不同器械類別和臨床應用中的療效和安全性特徵。

簡明扼要的結論整合了技術進步、當前供應鏈狀況、對臨床路徑的影響以及相關人員。

綜合上述分析，心臟輔助裝置領域技術蓬勃發展，但運作複雜，多種相互依存的因素共同影響短期選擇和長期策略。經經皮輸送和連續流架構的技術進步正在拓展手術可能性，並重塑臨床決策。同時，數據驅動的護理模式正在改變植入後的預期，並為裝置本身以外的附加價值服務創造機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 心臟輔助設備市場：依產品類型分類

  • 雙心室輔助裝置
  • 左心室輔助裝置
  • 經皮心室輔助裝置
    • 葉輪
    • 串聯心臟
  • 右心室輔助裝置
  • 人工心臟

第9章 心臟輔助設備市場：依運作模式分類

  • 連續流
    • 軸流式
    • 圓神流
  • 脈衝流

第10章：按治療持續時間分類的心臟輔助設備市場

  • 長期
  • 短期

第11章 依臨床應用分類的心臟輔助設備市場

  • 彌合復甦差距
  • 彌合移植差距
  • 最終治療

第12章 心臟輔助設備市場：依最終用戶分類

  • 醫院
  • 專科診所

第13章 心臟輔助設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 心臟輔助設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 心臟輔助設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國心臟輔助設備市場

第17章：中國心臟輔助設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AlivCor Inc.
  • Bardy Diagnostics, Inc.
  • Berlin Heart GmbH
  • BiVACOR Inc.
  • Boston Scientific Corporation
  • Cardiac Insight, Inc.
  • Cardiobridge GmbH
  • CorInnova, Inc.
  • CorWave SA
  • GE HealthCare Technologies Inc.
  • Getinge AB
  • Hill-Rom Holdings, Inc.
  • Jarvik Heart Inc.
  • Koninklijke Philips NV
  • LivaNova PLC
  • Medtronic PLC
  • OSI Systems, Inc.
  • Supira Medical
  • Teleflex Incorporated
  • Terumo Corporation
  • Xenios AG
Product Code: MRR-F97DD5A7DF05

The Cardiac Assist Devices Market was valued at USD 1.65 billion in 2025 and is projected to grow to USD 1.75 billion in 2026, with a CAGR of 6.84%, reaching USD 2.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.65 billion
Estimated Year [2026] USD 1.75 billion
Forecast Year [2032] USD 2.63 billion
CAGR (%) 6.84%

Comprehensive introduction to cardiac assist devices highlighting clinical evolution, technology convergence, and strategic priorities for stakeholders

Cardiac assist devices have evolved from niche rescue therapies into central components of contemporary advanced heart failure management. Over the past two decades, improvements in device miniaturization, surgical technique, and postoperative care have shifted clinical expectations and broadened the pool of patients who may benefit from mechanical circulatory support. Concurrent advances in imaging, hemodynamic monitoring, and anticoagulation management have further increased the procedural safety profile, enabling earlier and more decisive clinical interventions.

Clinicians now integrate device selection and timing into multidisciplinary care pathways that include heart failure specialists, cardiac surgeons, intensivists, and rehabilitation teams. This integrated model emphasizes patient-centered endpoints such as functional recovery, quality of life, and reduction of rehospitalizations alongside traditional survival metrics. Device developers have responded with modular product families, hybrid approaches bridging temporary to durable support, and user-centered incremental innovations that reduce implantation complexity.

Regulators and payers have likewise adapted, instituting evidence frameworks and real-world data collection that inform reimbursement sequences and coverage policies. Consequently, technology developers must now navigate not only engineering and clinical hurdles but also the expanding expectations of health systems for demonstrable outcomes. As stakeholders assess strategic options, understanding the interplay between clinical need, device capability, and system-level constraints becomes critical for making informed decisions about investment, adoption, and clinical protocol evolution.

In-depth analysis of converging technological, clinical, and reimbursement shifts reshaping cardiac assist device innovation and care delivery

The landscape for cardiac assist devices is undergoing transformative shifts driven by converging forces across technology, clinical practice, and health system economics. Miniaturization of pump components and the refinement of percutaneous access techniques have expanded indications for less invasive support, enabling earlier intervention in acutely decompensated patients and offering bridge strategies that can be deployed outside traditional operating rooms. Concurrently, clinicians are recalibrating patient selection criteria based on improved risk stratification tools and biomarkers, which has led to more personalized device choices and therapy timing.

In parallel, data-driven monitoring and remote telemetry have redefined post-implant care, facilitating outpatient management protocols and reducing hospital length of stay. These capabilities have important implications for device design and service models, shifting some value propositions from device durability alone toward integrated solutions encompassing remote monitoring, predictive maintenance, and digital care workflows. Reimbursement models are adapting, with increasing emphasis on bundled care outcomes and value-based arrangements that prioritize quality metrics and total cost of care rather than procedural volume.

Finally, the competitive landscape is evolving as established implantable device manufacturers, surgical device specialists, and new entrants with expertise in transcatheter systems converge. This competitive convergence has intensified partnerships, licensing agreements, and targeted acquisitions intended to bridge gaps across therapy duration, access modality, and clinical application. As a result, stakeholders must adopt adaptive strategies that anticipate continued technological refinement and shifting care delivery expectations.

Cumulative analysis of 2025 United States tariff adjustments and their strategic implications for cardiac assist device supply chains and procurement strategies

The set of tariff adjustments announced for 2025 in the United States introduces tangible implications for supply chain design, sourcing decisions, and procurement strategy across the cardiac assist device ecosystem. Manufacturers that rely on international supply chains for precision components, pump assemblies, or proprietary consumables may experience margin compression if tariff-induced cost increases cannot be absorbed or passed through to purchasers. Consequently, procurement teams within health systems and group purchasing organizations are likely to scrutinize total delivered cost more closely, while suppliers may revisit contract terms and hedging strategies to manage exposure.

These tariff adjustments also affect strategic manufacturing footprints. Some companies will consider nearshoring critical components or expanding domestic manufacturing capacity to mitigate tariff sensitivity and improve supply continuity. Such shifts require capital allocation, regulatory revalidation of production sites, and potential reconfiguration of logistics networks, all of which have lead times that extend beyond immediate procurement cycles. In the near term, contractual renegotiation and volume-based sourcing arrangements will be important levers for both suppliers and buyers to preserve access and control pricing volatility.

Clinicians and hospital administrators should anticipate potential downstream effects on device availability and value-based contracting. To navigate this environment, cross-functional teams that include supply chain, clinical leadership, and contracting specialists should develop scenario plans that balance short-term operational continuity with long-term strategic resilience. By doing so, organizations can protect patient access to critical therapies while positioning themselves to benefit from supply chain optimization opportunities that arise from tariff-driven adjustments.

Key segmentation insights that delineate product types, operational modalities, clinical applications, therapy durations, and end-user implications for adoption

A rigorous segmentation framework clarifies how product families, operational modes, clinical intent, therapy duration, and end users interact to shape adoption pathways and development priorities. Based on product type, device categories range from biventricular assist devices and left ventricular assist devices to percutaneous ventricular assist devices, right ventricular assist devices, and total artificial hearts, with percutaneous options further differentiated by platforms such as Impella and TandemHeart; each product category presents distinct clinical use cases, procedural workflows, and service expectations that influence how institutions prioritize adoption.

Based on mode of operation, devices are studied across continuous flow and pulsatile flow technologies, with continuous flow devices further segmented into axial flow and centrifugal flow architectures; these operational distinctions carry implications for hemocompatibility, thrombosis risk, and long-term durability considerations, and therefore influence clinician selection and post-implant management strategies. Based on clinical application, therapeutic roles include bridge to recovery, bridge to transplant, and destination therapy, each with unique registry requirements, outcome endpoints, and patient counseling priorities that affect device evaluation criteria.

Based on therapy duration, understanding contrasts between long-term and short-term use cases helps align product engineering with anticipated clinical pathways and follow-up needs, and based on end user, recognizing differences in utilization across hospitals and specialty clinics clarifies service models, training priorities, and capital acquisition approaches. Together, these cross-cutting segmentation lenses provide a structured way to evaluate technology fit, clinical workflow integration, and long-term support obligations.

Comprehensive regional insights outlining how regulatory, reimbursement, and clinical ecosystem differences shape cardiac assist device adoption across global regions

Regional dynamics significantly influence regulatory approaches, reimbursement paradigms, clinician practice patterns, and supply chain design, creating differentiated pathways for device commercialization and adoption. In the Americas, advanced cardiac centers continue to drive early adoption of minimally invasive and durable support strategies, supported by robust clinical registries, evolving coverage policies, and concentration of specialized surgical expertise; this environment favors technologies that demonstrate clear improvements in clinical outcomes and reductions in rehospitalization burden.

In Europe, the Middle East & Africa, regulatory harmonization efforts and national procurement frameworks shape pricing and access differently across jurisdictions, while pockets of clinical excellence in major metropolitan centers serve as hubs for advanced device adoption and investigator-led trials. Stakeholders operating in these regions must adapt to heterogeneous reimbursement landscapes and develop differentiated engagement strategies for national health services and private payers.

In Asia-Pacific, dynamic healthcare investment, expanding specialty care infrastructure, and rising cardiovascular disease burden create significant demand for scalable device solutions and services. However, regional regulatory timelines, reimbursement design, and local manufacturing preferences can materially affect go-to-market strategies. Across all regions, nuanced approaches to clinician education, local evidence generation, and post-market surveillance are essential to secure durable adoption and to align product support models with regional health system capabilities.

Strategic company-level insights revealing product innovation trends, collaborative partnerships, and service model evolution among device developers

Key industry participants are pursuing complementary strategies that encompass product innovation, service expansion, and collaborative arrangements with clinical centers to accelerate evidence generation and deployment. Leading device manufacturers are investing in iterative improvements to pump design, biocompatible materials, and integrated sensing to reduce complications and simplify implantation. At the same time, surgical device specialists and transcatheter innovators are exploring hybrid techniques and simplified access platforms that lower procedural complexity and broaden the range of eligible operators.

Partnerships between device developers and digital health vendors are increasing to enable remote monitoring, predictive maintenance algorithms, and patient engagement tools that extend the value proposition beyond the implant procedure. Several companies are also expanding service footprints to include training academies, simulation-based operator credentialing, and bundled service offerings that reduce institutional adoption friction. Strategic alliances with large health systems and academic centers are facilitating real-world evidence generation and registry development, which supports clinical guideline incorporation and payer discussions.

Emerging entrants with strengths in minimally invasive delivery or component manufacturing are prompting incumbents to reassess competitive postures, often resulting in licensing agreements or targeted acquisitions. For procurement teams and corporate strategists, tracking these moves provides early signals about future product roadmaps, integration priorities, and potential new service models that could alter procurement criteria and clinical workflows.

Actionable recommendations for industry leaders to enhance product relevance, supply chain resilience, evidence generation, and service-based commercial models

Industry leaders should prioritize a set of actionable initiatives to maintain clinical relevance, protect margins, and accelerate adoption within constrained procurement environments. First, invest in modular product strategies that allow incremental upgrades to key subsystems, such as controllers and sensors, reducing the need for full-system replacement while improving the lifetime value proposition for hospitals. Second, develop comprehensive evidence plans that extend beyond pivotal trials to include registries, real-world outcomes, and health economic analyses that speak directly to payer and hospital procurement concerns.

Third, strengthen supply chain resilience through dual sourcing, nearshoring critical components, and strategic inventory policies to mitigate tariff and logistics-related disruptions. Fourth, expand service offerings to include training, remote monitoring, and lifecycle maintenance programs that reduce institutional barriers to adoption and create recurring revenue streams. Fifth, engage proactively with regulators and payers to clarify evidence expectations and to pilot value-based contracting arrangements that align incentives across stakeholders.

Finally, cultivate clinician partnerships through centers of excellence, investigator-initiated trial support, and co-development arrangements that prioritize user experience and workflow integration. By executing these initiatives in parallel, industry leaders can better align product development with health system demands, buffer against supply chain shocks, and accelerate meaningful clinical uptake.

Transparent and multi-source research methodology combining primary clinician interviews, registry analysis, regulatory review, and scenario-based assessments

The research methodology integrates multiple evidence streams to ensure robust, reproducible insights that are actionable for clinical, commercial, and regulatory stakeholders. Primary research includes structured interviews with cardiac surgeons, heart failure specialists, interventional cardiologists, and procurement leaders to capture frontline perspectives on device performance, procedural workflows, and adoption barriers. These qualitative inputs are triangulated with clinical literature reviews, peer-reviewed trial outcomes, and device registries to validate efficacy and safety characteristics across device categories and clinical applications.

Secondary data sources include regulatory filings, real-world evidence datasets, and technology whitepapers that provide context on device approvals, post-market surveillance findings, and evolving standard-of-care benchmarks. The methodology also uses scenario analysis and sensitivity assessments to explore the operational and financial implications of supply chain disruptions, regulatory changes, and reimbursement shifts. Throughout the process, findings are subjected to internal peer review by clinical and technical experts to ensure interpretive rigor and to minimize bias.

Transparency is maintained by documenting data sources, interview protocols, and analytical assumptions, while confidentiality safeguards protect participating clinicians and institutions. The resulting methodological approach balances depth of clinical validity with practical applicability, enabling stakeholders to translate insights into strategy, trial design input, and procurement planning.

Concise conclusion synthesizing technology advances, supply chain realities, clinical pathway implications, and strategic imperatives for stakeholders

Synthesis of the preceding analyses points to a cardiac assist device environment that is simultaneously technologically vibrant and operationally complex, with multiple interdependent forces shaping near-term choices and long-term strategy. Technological advances in percutaneous delivery and continuous flow architectures are expanding procedural possibilities and recalibrating clinical decision-making, while data-enabled care models are altering post-implant expectations and creating opportunities for value-added services that extend beyond the physical device.

At the same time, supply chain dynamics, including tariff effects and component sourcing decisions, are imposing new considerations on procurement and cost management. Regional regulatory and reimbursement heterogeneity requires differentiated commercialization roadmaps, and company strategies that emphasize partnerships, evidence generation, and service models are likely to be more resilient. For clinical leaders, aligning multidisciplinary care pathways and investing in training will be essential to capture the full potential of these technologies in improving patient-centered outcomes.

Overall, stakeholders who integrate device innovation with robust evidence generation, resilient supply chain planning, and service-oriented commercial approaches will be better positioned to deliver sustained clinical impact and operational value across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Assist Devices Market, by Product Type

  • 8.1. Biventricular Assist Device
  • 8.2. Left Ventricular Assist Device
  • 8.3. Percutaneous Ventricular Assist Device
    • 8.3.1. Impella
    • 8.3.2. TandemHeart
  • 8.4. Right Ventricular Assist Device
  • 8.5. Total Artificial Heart

9. Cardiac Assist Devices Market, by Mode Of Operation

  • 9.1. Continuous Flow
    • 9.1.1. Axial Flow
    • 9.1.2. Centrifugal Flow
  • 9.2. Pulsatile Flow

10. Cardiac Assist Devices Market, by Therapy Duration

  • 10.1. Long Term
  • 10.2. Short Term

11. Cardiac Assist Devices Market, by Clinical Application

  • 11.1. Bridge To Recovery
  • 11.2. Bridge To Transplant
  • 11.3. Destination Therapy

12. Cardiac Assist Devices Market, by End User

  • 12.1. Hospitals
  • 12.2. Specialty Clinics

13. Cardiac Assist Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiac Assist Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiac Assist Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cardiac Assist Devices Market

17. China Cardiac Assist Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AlivCor Inc.
  • 18.7. Bardy Diagnostics, Inc.
  • 18.8. Berlin Heart GmbH
  • 18.9. BiVACOR Inc.
  • 18.10. Boston Scientific Corporation
  • 18.11. Cardiac Insight, Inc.
  • 18.12. Cardiobridge GmbH
  • 18.13. CorInnova, Inc.
  • 18.14. CorWave SA
  • 18.15. GE HealthCare Technologies Inc.
  • 18.16. Getinge AB
  • 18.17. Hill-Rom Holdings, Inc.
  • 18.18. Jarvik Heart Inc.
  • 18.19. Koninklijke Philips N.V.
  • 18.20. LivaNova PLC
  • 18.21. Medtronic PLC
  • 18.22. OSI Systems, Inc.
  • 18.23. Supira Medical
  • 18.24. Teleflex Incorporated
  • 18.25. Terumo Corporation
  • 18.26. Xenios AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC ASSIST DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC ASSIST DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY IMPELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY IMPELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY IMPELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TANDEMHEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TANDEMHEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TANDEMHEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY AXIAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY AXIAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY AXIAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CENTRIFUGAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CENTRIFUGAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CENTRIFUGAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PULSATILE FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PULSATILE FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PULSATILE FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LONG TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LONG TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LONG TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SHORT TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SHORT TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SHORT TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO RECOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 142. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 143. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 164. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 165. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 166. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 167. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 173. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 174. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 175. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)